Researchers from Onxeo SA presented preclinical data for OX-425, a first-in-class oligodeoxynucleotide that operates as a poly (ADP-ribose) polymerase 1 (PARP-1) decoy, and which is being developed as anticancer agent.

The enzyme poly [ADP-ribose] polymerase 1 (PARP1) is well known for its role in DNA damage repair, and multiple FDA-approved PARP inhibitors are used to treat BRCA-mutated tumors. Now, researchers at the Wistar Institute have described a role for PARP in regulating the genome of Epstein-Barr virus.